WFRF:(Finazzi Guido)
Search: WFRF:(Finazzi Guido) > (2007) > Proposals and ratio...
- 1 of 1
- Previous record
- Next record
- To hitlist
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis : recommendations from an ad hoc international expert panel
- Tefferi, Ayalew (author)
- Thiele, Juergen (author)
- Orazi, Attilio (author)
- show more...
- Kvasnicka, Hans Michael (author)
- Barbui, Tiziano (author)
- Hanson, Curtis A. (author)
- Barosi, Giovanni (author)
- Verstovsek, Srdan (author)
- Mesa, Ruben (author)
- Reilly, John T. (author)
- Gisslinger, Heinz (author)
- Vannucchi, Alessandro M. (author)
- Cervantes, Francisco (author)
- Finazzi, Guido (author)
- Hoffman, Ronald (author)
- Gilliland, D Gary. (author)
- Bloomfield, Clara D. (author)
- Vardiman, James W. (author)
- show less...
- (creator_code:org_t)
- American Society of Hematology, 2007
- 2007
- English.
- In: Blood. - : American Society of Hematology. - 0006-4971 .- 1528-0020. ; 110:4, s. 1092-1097
- Journal article (peer-reviewed)
Abstract
Subject headings
Close
- The Janus kinase 2 mutation, JAK2V617F, is myeloid neoplasm-specific; its presence excludes secondary polycythemia, or thrombocytosis or bone marrow fibrosis from other causes. Furthermore, JAK2V617F or a JAK2 exon 12 mutation is present in virtually all patients with polycythemia vera (PV) whereas JAK2V617F also occurs in approximately half of patients with essential thrombocythemia (ET) or primary myelofibrosis (PMF). Therefore, JAK2 mutation screening holds the promise of a decisive diagnostic test in PV while being complementary to histology for the diagnosis of ET and PMF; the combination of molecular testing and histological review should also facilitate diagnosis of ET associated with borderline thrombocytosis. Accordingly, revision of the current World Health Organization (WHO) diagnostic criteria for PV, ET, and PMF is warranted; JAK2 mutation analysis should be listed as a major criterion for PV diagnosis and the platelet count threshold for ET diagnosis can be lowered from 600 to 450 x 109/L. The current document was prepared by an international expert panel of pathologists and clinical investigators in myeloproliferative disorders; it was subsequently presented to members of the Clinical Advisory Committee for the revision of the WHO Classification of Myeloid Neoplasms who endorsed the document and recommended its adoption by the WHO.
Keyword
- MEDICINE
- MEDICIN
Publication and Content Type
- ref (subject category)
- art (subject category)
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Tefferi, Ayalew
- Thiele, Juergen
- Orazi, Attilio
- Kvasnicka, Hans ...
- Barbui, Tiziano
- Hanson, Curtis A ...
- show more...
- Barosi, Giovanni
- Verstovsek, Srda ...
- Birgegård, Gunna ...
- Mesa, Ruben
- Reilly, John T.
- Gisslinger, Hein ...
- Vannucchi, Aless ...
- Cervantes, Franc ...
- Finazzi, Guido
- Hoffman, Ronald
- Gilliland, D Gar ...
- Bloomfield, Clar ...
- Vardiman, James ...
- show less...
- Articles in the publication
- Blood
- By the university
- Uppsala University
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
